COSTA MESA, CA / ACCESSWIRE / January 10, 2017 / NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced the closing of its
Preferred Stock financing for gross proceeds of $1,200,000. Roth Capital Partners acted as the exclusive placement agent for the
transaction.
ABOUT NEMUS BIOSCIENCE, INC.
The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and
commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets. Utilizing certain
proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver
cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the
potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The
Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in
early-stage drug development. For more information, visit www.nemusbioscience.com.
CONTACTS:
Adam Holdsworth, Investor Relations Email: adamh@pcgadvisory.com Phone: 646-862-4607
Janet Vasquez, Public Relations Email: jvasquez@jvprny.com Phone: 212-645-5498
SOURCE: NEMUS Bioscience, Inc.
